Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies

Group 1 - Onco-Innovations Limited has announced that Dalton Pharma Services has started manufacturing its proprietary nanoparticle formulation, PEO-b-PBz-CL, which is essential for the company's drug delivery platform [1] - The nanoparticle formulation is intended to be used in conjunction with Onco's proprietary Polynucleotide Kinase Phosphatase (PNKP) inhibitor [1] - The manufacturing initiative aims to produce the nanoparticle material necessary to advance preclinical studies [1]